Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531391 | 1.00 | HTT (0.53) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL12429752 | 1.00 | HTT (0.53) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL29171368 | 0.84 | HTT (0.58) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL11664059 | 0.84 | MAPT (0.49) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL2074687 | 0.84 | HTT (0.54) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL12374412 | 0.84 | ALDH1A1 (0.49) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL1578485 | 0.83 | MCHR1 (0.47) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL27511188 | 0.83 | LMNA (0.43) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL27509361 | 0.83 | LMNA (0.43) | HTTSMN1; SMN2LMNATDP1ALDH1A1 | |
| SCHEMBL1578564 | 0.83 | MCHR1 (0.47) | HTTSMN1; SMN2LMNATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346872-B1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8754211-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-8618115-B2 | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| US-8580959-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8415386-B2 | Azolopyrrolone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| EP-1948665-B1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1948665-B1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2010047956-A9 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110195934-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| EP-2346873-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2298776-A1 | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010047956-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-29 | — | — | WO | disclosed |
| EP-1948665-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007050726-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050726-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195934-A1 | AZOLOPYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MC1R, MCHR1, MCHR2 | HTT 1607/4885SMN1; SMN2 4741/4885LMNA 4699/4885 |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | HTT 704/4885SMN1; SMN2 1571/4885LMNA 3409/4885 |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | HTT 965/4885SMN1; SMN2 4324/4885LMNA 3998/4885 |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | HTT 965/4885SMN1; SMN2 4324/4885LMNA 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.